Table 1.
Prevalence of Concurrent Oral and Genital High-Risk Human Papillomavirus (HR-HPV) Infections among Four Groups of HR-HPV for Total Population, Men, and Women (NHANES: 2013–2016 for Men, 2009–2016 for Women).
| HR-HPV Groups | Oral HR-HPV Infection Given Genital Infection | |||||
|---|---|---|---|---|---|---|
| Yes |
No |
Total |
||||
| n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | |
|
| ||||||
| Total Population | ||||||
| HR-HPVa | OR = 3.44; Chi2 = 162.81, p-value < .005 | |||||
| Yes | 172 | 2.1 (1.7, 2.7) | 2649 | 24.3 (22.8, 25.9) | 2821 | 26.4 (24.8, 28.2) |
| No | 158 | 1.8 (1.4, 2.3) | 7355 | 71.8 (69.9, 73.5) | 7513 | 73.6 (71.8, 75.2) |
| Total | 330 | 3.9 (3.3, 4.6) | 10004 | 96.1 (95.4, 96.7) | 10334 | |
| HR 9V Typesb | OR = 3.42; Chi2 = 65.51, p-value < .005 | |||||
| Yes | 46 | 0.56 (0.37, 0.84) | 1231 | 11.2 (10.3, 12.1) | 1277 | 11.7 (10.8, 12.7) |
| No | 85 | 1.3 (0.93, 1.7) | 8972 | 87.0 (85.9, 88.0) | 9057 | 88.3 (87.3, 89.2) |
| Total | 131 | 1.8 (1.5, 2.2) | 10203 | 98.2 (97.8, 98.5) | 10334 | |
| HPV 16, 18, or 45c | OR = 4.77; Chi2 = 75.60, p-value < .005 | |||||
| Yes | 32 | 0.34 (0.22, 0.55) | 676 | 6.5 (5.8, 7.2) | 708 | 6.8 (6.2, 7.6) |
| No | 64 | 1.0 (0.78, 1.3) | 9562 | 92.1 (91.4, 92.8) | 9626 | 93.2 (92.4, 93.8) |
| Total | 96 | 1.4 (1.1, 1.7) | 10238 | 98.6 (98.3, 98.9) | 10334 | |
| HPV 16d | OR = 5.4; Chi2 = 44.70, p-value < .005 | |||||
| Yes | 18 | 0.15 (0.09, 0.25) | 336 | 3.6 (3.1, 4.2) | 354 | 3.7 (3.2, 4.3) |
| No | 46 | 0.75 (0.55, 1.0) | 9934 | 95.5 (94.9, 96.1) | 9980 | 96.3(95.7, 96.8) |
| Total | 64 | 0.90 (0.70, 1.1) | 10270 | 99.1 (98.9, 99.3) | 10334 | |
| Men | ||||||
| HR-HPVa | OR = 3.6; Chi2 = 84.16, p-value < .005 | |||||
| Yes | 109 | 3.5 (2.7, 4.6) | 808 | 24.6 (22.4, 26.9) | 917 | 28.1 (25.5, 30.8) |
| No | 92 | 2.7 (2.0, 3.7) | 2232 | 69.2 (66.2, 72.0) | 2324 | 71.9 (69.2, 74.5) |
| Total | 201 | 6.3 (5.2, 7.6) | 3040 | 93.7 (92.4, 94.8) | 3241 | |
| HR 9V Typesb | OR = 2.96; Chi2 = 24.21, p-value < .005 | |||||
| Yes | 27 | 0.86 (0.52, 1.4) | 378 | 11.5 (10.0, 13.0) | 405 | 12.3 (10.8, 14.0) |
| No | 53 | 2.2 (1.5, 3.1) | 2783 | 85.5 (83.6, 87.2) | 2836 | 87.7(86.0, 89.2) |
| Total | 80 | 3.0 (2.3, 3.9) | 3161 | 97.0 (96.1, 97.7) | 3241 | |
| HPV 16, 18, or 45c | OR = 3.71; Chi2 = 23.36, p-value < .005 | |||||
| Yes | 18 | 0.50 (0.27, 0.91) | 210 | 6.8 (5.7, 8.0) | 228 | 7.3 (6.3, 8.4) |
| No | 42 | 1.8 (1.3, 2.4) | 2971 | 90.9 (89.7, 92.0) | 3013 | 92.7 (91.6, 93.7) |
| Total | 60 | 2.3 (1.8, 3.0) | 3181 | 97.7 (97.0, 98.2) | 3241 | |
| HPV 16d | OR = 3.26; Chi2 = 7.41, p-value < .05 | |||||
| Yes | 10 | 0.17 (0.09, 0.34)^ | 109 | 3.8 (3.0, 4.8) | 119 | 4.0 (3.2, 4.9) |
| No | 32 | 1.3 (0.93, 1.9) | 3090 | 94.7 (93.6, 95.6) | 3122 | 96.0 (95.1, 96.8) |
| Total | 42 | 1.5 (1.1, 2.0) | 3199 | 98.5 (98.0, 98.9) | 3241 | |
| Women | ||||||
| HR-HPVa | OR = 2.59; Chi2 = 27.68, p-value < .005 | |||||
| Yes | 63 | 0.76 (0.56, 1.0) | 1841 | 24.1 (22.6, 25.7) | 1904 | 24.8 (23.3, 26.5) |
| No | 66 | 0.90 (0.65, 1.2) | 5123 | 74.3 (72.7, 75.8) | 5189 | 75.2 (73.5, 76.7) |
| Total | 129 | 1.7 (1.3, 2.1) | 6964 | 98.3 (97.9, 98.7) | 7093 | |
| HR 9V Typesb | OR = 5.33; Chi2 = 39.15, p-value < .005 | |||||
| Yes | 19 | 0.27 (0.15, 0.46) | 853 | 10.9 (9.9, 11.9) | 872 | 11.1 (10.2, 12.2) |
| No | 32 | 0.41 (0.26, 0.64) | 6189 | 88.5 (87.4, 89.5) | 6221 | 88.9 (87.8, 89.8) |
| Total | 51 | 0.67 (0.45, 0.99) | 7042 | 99.3 (99.0, 99.5) | 7093 | |
| HPV 16, 18, or 45c | OR = 10.62; Chi2 = 69.37, p-value < .005 | |||||
| Yes | 14 | 0.20 (0.10, 0.40)^ | 466 | 6.2 (5.5, 7.1) | 480 | 6.4 (5.7, 7.3) |
| No | 22 | 0.28 (0.16, 0.49) | 6591 | 93.3 (92.4, 94.1) | 6613 | 93.6 (92.7, 94.3) |
| Total | 36 | 0.48 (0.28, 0.80) | 7057 | 99.5 (99.2, 99.7) | 7093 | |
| HPV 16d | OR = 18.76; Chi2 = 90.90, p-value < .005 | |||||
| Yes | 8 | 0.13 (0.06, 0.30)^ | 227 | 3.4 (2.8, 4.0) | 235 | 3.5 (2.9, 4.2) |
| No | 14 | 0.20 (0.10, 0.40)^ | 6844 | 96.3 (95.6, 96.9) | 6858 | 96.5 (95.8, 97.1) |
| Total | 22 | 0.33 (0.19, 0.59) | 7071 | 99.7 (99.4, 99.8) | 7093 | |
NHANES: National Health and Nutrition Examination Survey
CI: Confidence Interval
OR: Odds Ratio
a
HR-HPV: All 18 high-risk types
b
HPV 9V Types: HR-HPV types covered in the 9-valent vaccine (types 16, 18, 31, 33, 45, 52, and 58)
c
HPV 16, 18, 45: The most common types found in cervical cancers
d
HPV 16: The most common type found in HPV-associated cancers
^
The relative standard error of the weighted prevalence estimate was > 30%